Valganciclovir

• CAT Number: I002292
• CAS Number: 175865-60-8
• Molecular Formula: C14H22N6O5
• Molecular Weight: 354.36
• Purity: ≥95%
• Synonyms: Cymeval; Valganciclovir [INN:BAN]; L-Valine, ester with ganciclovir
• Target: CMV
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
• InChI: InChI=1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1
• InChIKey: WPVFJKSGQUFQAP-GKAPJAKFSA-N
• SMILES: CC(C)[C@@H](C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N

Valganciclovir（Cat No.:I002292）is an antiviral medication used to treat infections caused by cytomegalovirus (CMV), particularly in immunocompromised patients, such as those undergoing organ transplantation or with HIV/AIDS. It works by inhibiting CMV replication through the inhibition of viral DNA synthesis. Valganciclovir is the oral prodrug of ganciclovir, offering improved bioavailability. It is primarily used to prevent and treat CMV retinitis and CMV disease in transplant recipients. While effective, it requires careful monitoring for potential side effects, including neutropenia, thrombocytopenia, and renal toxicity.

Reference

[1]. Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9.
[2]. Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun;14(3):259-67.
[3]. O/'Brien S, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15;111(4):1816-9.